WO2024052756A1 - Use of an extract of sichuan pepper for a skin treatment and a composition suitable for this use. - Google Patents
Use of an extract of sichuan pepper for a skin treatment and a composition suitable for this use. Download PDFInfo
- Publication number
- WO2024052756A1 WO2024052756A1 PCT/IB2023/058397 IB2023058397W WO2024052756A1 WO 2024052756 A1 WO2024052756 A1 WO 2024052756A1 IB 2023058397 W IB2023058397 W IB 2023058397W WO 2024052756 A1 WO2024052756 A1 WO 2024052756A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- skin
- use according
- extract
- extract according
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 123
- 238000011282 treatment Methods 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 244000089698 Zanthoxylum simulans Species 0.000 title claims abstract description 25
- 235000009932 Zanthoxylum simulans Nutrition 0.000 title abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 35
- 239000002537 cosmetic Substances 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 210000004761 scalp Anatomy 0.000 claims abstract description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 10
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 10
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 10
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 10
- 230000000699 topical effect Effects 0.000 claims abstract description 10
- 206010000496 acne Diseases 0.000 claims abstract description 9
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 7
- 206010039792 Seborrhoea Diseases 0.000 claims abstract description 6
- 230000037312 oily skin Effects 0.000 claims abstract description 6
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 235000021028 berry Nutrition 0.000 claims description 27
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 12
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 11
- 210000002374 sebum Anatomy 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 235000019626 lipase activity Nutrition 0.000 claims description 9
- 230000036642 wellbeing Effects 0.000 claims description 9
- 208000001840 Dandruff Diseases 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 230000002500 effect on skin Effects 0.000 claims description 8
- 230000002996 emotional effect Effects 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- 230000029087 digestion Effects 0.000 claims description 7
- 230000003020 moisturizing effect Effects 0.000 claims description 7
- 230000008591 skin barrier function Effects 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 238000002803 maceration Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 230000006862 enzymatic digestion Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000005325 percolation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 230000003014 reinforcing effect Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims 1
- 229920002549 elastin Polymers 0.000 abstract description 12
- 102000016942 Elastin Human genes 0.000 abstract description 11
- 108010014258 Elastin Proteins 0.000 abstract description 11
- 102000008186 Collagen Human genes 0.000 abstract description 9
- 108010035532 Collagen Proteins 0.000 abstract description 9
- 239000004367 Lipase Substances 0.000 abstract description 9
- 229920001436 collagen Polymers 0.000 abstract description 9
- 102000004882 Lipase Human genes 0.000 abstract description 7
- 108090001060 Lipase Proteins 0.000 abstract description 7
- 235000019421 lipase Nutrition 0.000 abstract description 7
- 241000736262 Microbiota Species 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 229940116257 pepper extract Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 61
- 239000000047 product Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 26
- 210000002510 keratinocyte Anatomy 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 20
- 239000006071 cream Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 239000002609 medium Substances 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 230000008451 emotion Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000010410 layer Substances 0.000 description 12
- 241000186245 Corynebacterium xerosis Species 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 210000004243 sweat Anatomy 0.000 description 11
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 10
- 230000037007 arousal Effects 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000035943 smell Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 239000011148 porous material Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- FBUBVLUPUDBFME-UHFFFAOYSA-N Xanthoxylin Chemical compound COC1=CC(O)=C(C(C)=O)C(OC)=C1 FBUBVLUPUDBFME-UHFFFAOYSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000002781 deodorant agent Substances 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000020095 red wine Nutrition 0.000 description 6
- 230000037307 sensitive skin Effects 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 235000019606 astringent taste Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000555676 Malassezia Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 4
- 241001135917 Vitellaria paradoxa Species 0.000 description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000000736 corneocyte Anatomy 0.000 description 4
- 210000000720 eyelash Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000004378 sebocyte Anatomy 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 229960003500 triclosan Drugs 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241001079064 Zanthoxylum schinifolium Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001166 anti-perspirative effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- -1 calming Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000004709 eyebrow Anatomy 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 159000000013 aluminium salts Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical compound [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000005550 inflammation mediator Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- KNMNNEPMKDJBDW-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2,6-dimethylphenoxy)propan-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC(C)COC1=C(C)C=CC=C1C KNMNNEPMKDJBDW-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- ICBBPHMFVQOHJF-UHFFFAOYSA-N 1-phenoxyethanol propane-1,2,3-triol Chemical compound O(C1=CC=CC=C1)C(C)O.OCC(O)CO ICBBPHMFVQOHJF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000928573 Cutibacterium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- HYZDYRHKPFPODK-CYGHRXIMSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HYZDYRHKPFPODK-CYGHRXIMSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229940095077 behentrimonium methosulfate Drugs 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- QIVLQXGSQSFTIF-UHFFFAOYSA-M docosyl(trimethyl)azanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C QIVLQXGSQSFTIF-UHFFFAOYSA-M 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000000485 pigmenting effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940098385 triisostearin Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- AZOOXWWPWARTFV-UHFFFAOYSA-N zirconium hydrochloride Chemical class Cl.[Zr] AZOOXWWPWARTFV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Definitions
- the present invention relates to the use of an extract of Sichuan pepper, more particularly of berries, and a composition comprising said extract for a cosmetic or dermatological treatment, in particular a topical treatment.
- Cosmetic or cosmeceutical treatment means a treatment which treats healthy skin and/or skin appendages, said treatment being intended to improve or beautify their appearance and condition. Such treatment has no therapeutic purpose.
- the present invention relates in particular to the cosmetic and dermo-pharmaceutical industries, which manufacture and/or use products intended for the treatment of the skin, including the scalp, mucous membranes and appendages (such as hair, eyelashes, eyebrows, nails) of mammals, animals or humans, for improving their appearance and/or their general condition.
- Human odour is genetically controlled and systematically influenced by gender and ethnicity, along with emotional, physiological and environmental factors (influence of sweat composition and quantity). Body malodour affects social interaction by reducing self-confidence.
- Body odour originates from sweat secreted by the sudoriferous glands, which can be of two types:
- Eccrine sweat glands are found mainly on the hands palms and the feet soles. Eccrine sweat is responsible for regulating body temperature.
- Apocrine sweat glands are bigger, confined to shaggy areas, mainly the armpits, perineal area and scalp. Apocrine sweat is responsible for body odour.
- the apocrine sweat contains large, odourless, and non-volatile molecules. Odour is generated when these molecules are lysed into small, volatile odorous entities. This lysis is carried out by enzymes including lipases, which are themselves produced by skin bacteria.
- antiperspirant or deodorant on a daily basis.
- Most of these products are antibacterial and/or contain aluminium salts. These products have the ability to tighten the pores of the skin, and therefore reduce the flow of sweat, but have numerous disadvantages, including an increased risk of breast cancer.
- the aim of the present invention is to respond to all of these demands, namely to offer a complete cosmetic product and treatment, in particular a "holistic" treatment, and more specifically to respond to the demand for a body odour treatment.
- Body odour treatment » means an anti-odour treatment designed to reduce, mask, eliminate, absorb and/or limit the generation of the bad odour resulting from the decomposition of sweat by bacteria.
- the applicant provides the use of a Sichuan berries extract of species Zanthoxylum bungeanum or Zanthoxylum simula ns for a non-therapeutic cosmetic treatment of the skin and its appendages.
- the treatment is a topical treatment.
- Topical treatment » or « topical use » means according to the invention, an application that is intended to act where it is applied: skin, mucosa and/or appendages.
- the Sichuan pepper tree is defined by one of these two species: Zanthoxylum bungeanum and Zanthoxylum simulans . It is from the Sichuan region (China).
- the Sichuan pepper tree used according to the invention is preferably Zanthoxylum bungeanum .
- Sichuan berries come from the pericarp of the fruit of the Sichuan pepper tree.
- ECM dermal extracellular matrix
- the barrier is therefore less fragile, which contributes to the flexibility of the epidermis.
- oxidative and radical forms are linked to age and/or repeated environmental stresses, such as UV rays. Radicals and reactive oxygen species attack membrane lipids and/or functional proteins in the dermal ECM, such as collagen and elastin.
- glycation it also affects proteins and/or reducing sugars. These interactions with proteins and/or reducing sugars alter the mechanical and elastic properties of the dermal ECM, which becomes less flexible, more rigid, but also more flabby and less reactive. Visually, this results in the appearance of fine lines and wrinkles, and a skin that is dull, flaccid, lacking radiance, tired-looking, and lacking tone and suppleness.
- Sebum leads to excessive growth of dandruff-causing bacteria such as Malassezia fungi on the scalp. This fungus is responsible for the formation of dandruff and the itching associated with it.
- Malassezia release lipases to ensure their growth, which hydrolyse triacylglycerols into monoacylglycerols and then into fatty acids and glycerol. These free fatty acids inhibit the growth of other micro-organisms, encourage the proliferation of Malassezia and penetrate the stratum corneum , causing damage to the skin barrier.
- Hyaluronic acid is a major constituent of the epidermis contributing to the barrier function as well as to the maintaining of a satisfactory hydration of the skin. It is capable of absorbing 1,000 times its own weight in water. It is in the form of an aqueous and nourishing gel which fills the spaces between the keratinocytes. It prevents from dryness of the skin, which is known to alter the texture of the skin, giving it a rough touch.
- the differentiation of the keratinocytes begins from the basal layer of the epidermis.
- the epidermis is divided into a plurality of layers:
- the deeper layer is the basal layer, comprising keratinocytes
- stratum corneum the most superficial layer is the stratum corneum , consisting of a plurality of keratinocyte layers at the terminal stage of their differentiation and called corneocytes.
- This highly water-insoluble corneal envelope is composed of anucleate corneal cells, without cytoplasmic organelles and completely keratinised.
- Keratinocytes migrate from the deeper layer to the most superficial layer, differentiating themselves into corneocytes.
- the stratum corneum is a semi-permeable protective layer that prevents water loss and keeps the skin hydrated. It is composed of the corneocytes, lipids and lamellar bodies, and "natural moisturizing factors" (NMF - substances capable of binding water in the stratum corneum ) which maintain the level of skin moisture at an optimum level.
- NMF natural moisturizing factors
- TEWL transepidermal water loss
- a skin soothing treatment thanks to the reduction of inflammation mediators responsible for the appearance of skin micro-inflammations causing feelings of tightness and discomfort, and also thanks to a moisturizing treatment as described above, resulting in a skin that is softer and less rough.
- EEG electroencephalogram
- cosmetic effects can be envisaged according to the invention separately or in combination, making it possible in particular to offer a use of "holistic” type combining olfactory, beautifying, sensorial and emotional effects.
- the present invention provides the use of Sichuan berry extract of the species Zanthoxylum bungeanum or Zanthoxylum simulans , for at least one treatment selected from:
- the extract of Sichuan berries, of the species Zanthoxylum bungeanum or Zanthoxylum simulans , used according to the invention can be obtained by the usual solid/liquid extraction techniques including, for example, maceration, simple decoction, infusion, leaching, extraction under reflux, extraction by subcritical or supercritical fluid, extraction by means of ultrasound or microwaves or any other physical and/or chemical method, such as percolation, digestion, cryoextraction, enzymatic digestion, etc.
- the extract is obtained by extraction under reflux, maceration, decoction, infusion, leaching, extraction by subcritical or supercritical fluid, extraction by means of ultrasound or microwaves, percolation, digestion, cryoextraction, or enzymatic digestion.
- Maceration » means a process consisting of soaking a plant or part of a plant in an extraction solvent at room temperature.
- Infusion » means a process consisting of bringing the extraction solvent to the boil before pouring it onto the plant or part of the plant.
- Decoction » means a process consisting of blending the plant or the part of plant with the extraction solvent, then heating the mixture at the boiling point.
- Digestion » means a process consisting of blending the plant or the part of plant with the extraction solvent, then heating the mixture below boiling point.
- the extract is obtained by digestion of Sichuan berries in at least one aqueous, alcoholic, hydroalcoholic, glycolic or lipidic solvent or mixture thereof, such as water, a C1, C2, C3 or C4 alcohol, or a polyol selected from pentanediol, sorbitol, butylene glycol, pentylene glycol, propylene glycol, hexanol, caprylic/capric triglyceride (GTCC), a vegetable oil, or a mixture thereof.
- aqueous, alcoholic, hydroalcoholic, glycolic or lipidic solvent or mixture thereof such as water, a C1, C2, C3 or C4 alcohol, or a polyol selected from pentanediol, sorbitol, butylene glycol, pentylene glycol, propylene glycol, hexanol, caprylic/capric triglyceride (GTCC), a vegetable oil, or a mixture thereof.
- GTCC caprylic
- the extraction solvent is a glycolic solvent, and more preferably, the propylene glycol.
- the extract of Sichuan berry, Zanthoxylum bungeanum or Zanthoxylum simulans, used according to the invention comprises as main components xanthoxylin, polyphenols including flavonoids, carbohydrates, and proteins.
- This extract can be used as it is or in a composition, diluted in a physiologically acceptable medium.
- the nature of the medium is defined as a function of the properties of the Sichuan berry extract, and also as a function of the destination of the composition formed: simple ingredient, more sophisticated galenic form of a final composition for the consumer.
- Physiologically acceptable medium means according to the present invention, without limitation, an aqueous or hydro-alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a micro-emulsion, an aqueous gel, an anhydrous gel, a serum, a dispersion of vesicles, or a powder.
- compositions are suitable for topical or transdermal use, in contact with mucous membranes, appendages (nails, hair and body hair), scalp and skin of mammals, particularly human, compositions which may be ingested, or injected into the skin, without risk of toxicity, incompatibility, instability, allergic response, and others.
- This "physiologically acceptable medium” forms what is commonly called the excipient of the composition.
- the physiologically acceptable medium can be an aqueous, hydroglycolic or hydroalcoholic solution, or a water-in-oil emulsion, an oil-in-water emulsion, or a microemulsion.
- it is hydroglycolic.
- the physiologically acceptable medium is a blend of propylene glycol and water.
- the present invention covers a non-therapeutic, cosmetic or nutraceutical topical treatment method for beautifying or improving the appearance and general condition of skin and/or its appendages, and for treating their imperfections, by applying in a subject in need thereof an effective amount of at least one Sichuan berry extract according to the invention or a composition comprising it, in a physiologically acceptable medium.
- the effective amount of Sichuan berry extract according to the invention depends on the destination of the composition. It depends on various factors, such as the age, the condition of the patient, the severity of the disorder and the administration mode.
- An effective amount means a non-toxic amount enough to achieve the desired effect.
- a cosmetic composition according to the invention containing at least a Sichuan berry extract to be present in an effective amount, it is generally present in an amount ranging from 0.000001% and 15% based on the total weight of the composition, preferably ranging from 0.00001% and 10%, depending on the destination of the composition and the more or less pronounced desired effect. More preferably, the effective amount is between 0.0001% and 5% based on the total weight of the composition.
- the cosmetic treatment method according to the invention can be combined with one or more other treatment methods targeting the skin such as luminotherapy, heat or aromatherapy treatments.
- Devices with several compartments or kits may be proposed to apply the method described above which may include for example and non-restrictively, a first compartment containing a composition comprising the Sichuan berry extract of the invention, and in a second compartment an additional active ingredient, the compositions contained in the said first and second compartments in this case being considered to be a combination composition for simultaneous, separate or stepwise use in time, particularly in one of the treatment methods recited above.
- the European standard dosage of a cream is 2.72 mg/cm2/day/person and for a cosmetic body treatment the European standard dosage of a lotion is 0.5 mg/cm2/day/person.
- the Sichuan berry extract according to the invention may be associated with one or more other active ingredients at effective concentrations that can act synergistically or additionally for reinforcing and achieving the desired effects described for the invention, such as the following agents: filtering radiations, in particular UVA, UVB, IR or generated by blue light, hydrating, moisturizing, humectant, calming, muscle relaxant, slimming, restructuring, firming, replumping, lifting, smoothing, acting on blood microcirculation, inflammation, free radicals, anti-aging, anti-fine lines and wrinkles, lightening, acting on complexion, anti-glycation, anti-carbonylation, pro- pigmenting, acting on stratum corneum , on dermal -epidermal junction, on HSP protein production, on firmness, elasticity and tone of skin, on hair growth or anti-regrowth (including eyelashes and eyebrows), on eye contours (dark circles and under eye bags), peptides, vitamins, etc.
- active ingredients can be obtained
- the Personal Care Products Council (“International cosmetic ingredient dictionary & handbook” published by the "Cosmetic, Toiletry, and Fragrance Association, Inc.”, Washington, D.C.) describes a non-limited wide variety of cosmetic and pharmaceutical ingredients conventionally used in the skin care industry that can be used as additional ingredients in the compositions for the present invention, as long as they are physically and chemically compatible with the other ingredients of the composition and especially with the active ingredients of the present invention. Also, the nature of these additional ingredients should not unacceptably alter the benefits of the active ingredient of the invention. These additional ingredients can be synthetic or natural such as plants extracts or issued from a bio-fermentation process.
- the Sichuan berry extract according to the invention can be combined with at least one compound chosen among vitamin compounds, group B C, E, F, D and A, especially compounds as niacinamide or tocopherol, retinoids compounds as retinol, hyaluronic acid, hexamidine, ⁇ -lipoic acid, resveratrol or DHEA, peptides, aluminium salts, phosphate salts, magnesium oxide, zirconium hydrochloride salts, ceramides, which are classic active ingredients used in topical cosmetic or dermo-pharmaceutical compositions.
- the present invention provides the use of a Sichuan berries extract of species Zanthoxylum bungeanum or Zanthoxylum simulans , as described above, for the manufacture of a composition for a cosmetic treatment, as described above.
- composition for the use according to the invention can be provided in any galenic form (examples are given below) defined according to the composition destination and application site.
- a composition according to the invention can be applied to the face, body, neckline, scalp, hair, eyelashes, body hair, in any form or vehicle known to those skilled in the art, in particular in the form of a solution, dispersion, emulsion, paste or powder, individually or as a premix or vehicle individually or as a premix in a bound form, incorporated or adsorbed in vectors such as macro-, micro-, or nanocapsules, macro-, micro- or , nanospheres, liposomes, oleosomes or chylomicrons, macro-, micro-, or nanoparticles or macro-, micro or nanosponges, micro- or nanoemulsions, or adsorbed on organic polymer powders, talcs, bentonites, spores or exines, and other inorganic or organic supports.
- the galenic form of the composition can be a lotion, a cream, a butter, a milk, a solid form, a foam, a gel, a deodorant, an antiperspirant, a shampoo, a conditioner, a hair mask, a face mask, a shower gel, etc.
- the galenic form of the composition can be a cream for the face, the feet, and/or the whole body, a spray, an aerosol, a roll-on or a deodorant stick.
- the preferred galenic form may be a body lotion.
- the galenical formulations can enter in different product ranges for personal care and/or beauty products including skin care, cleaning, makeup, cleansing, sunscreen, artificial tanning, pre-shave, shaving or aftershave, moisturizer, humectant, emollient, conditioning, exfoliating, astringent, depilatories or antiperspirant, deodorant, etc.
- composition may be incorporated onto a non-woven or woven material, with natural or synthetic fibres, wool, or any material intended to come into contact with skin and that can be used in clothing, including tights and socks, shorty, day or night underwear, tissues, handkerchiefs or fabric to exert its cosmetic effect via the contact skin/textile and enable continuous topical delivery (cosmetic-textiles).
- a woven or non-woven fabric comprising at least one a Sichuan berry extract, for use in a non-therapeutical cosmetic treatment.
- FIG. 1 represents a photograph to illustrate the anti-lipase test, showing an agar medium containing glyceryl tributyrate which has not been brought into contact with the extract according to the invention (control case).
- Plant material Sichuan berries of the species Zanthoxylum bungeanum.
- berries are macerated in propylene glycol for 1 to 6 hours at 70 to 100°C, then the macerate is filtered to remove solid plant debris. Several successive filtrations are carried out, with a size of between 5 and 0.1 ⁇ m.
- the filtered macerate constitutes the berry extract according to the invention.
- a xanthoxylin-rich extract of Sichuan berries is obtained, with a xanthoxylin content of between 10 and 20% by weight based on the weight of the dry extract. This molecule is identified by high-performance thin-layer chromatography (HPTLC).
- the filtered macerate obtained is mixed with a physiologically acceptable matrix consisting of a water-propylene glycol mixture.
- the ratio of water to propylene glycol in the composition is between 0:100 and 30:70.
- Lipases are able to hydrolyse triglycerides having long fatty acid chains into glycerol and the corresponding volatile fatty acids responsible for unpleasant odour.
- Lipases are widely distributed in bacteria, yeasts and filamentous fungi. They are produced by Gram-positive bacteria such as Corynebacterium, Propionibacterium, Cutibacterium and Staphylococcus , as well as Gram-negative bacteria such as Pseudomonas .
- the genus Corynebacterium is mainly responsible for axillary malodour. Gram-negative bacteria bring almost no contribution to axillary malodour.
- Glycerol tributyrate substrate (fat-soluble) is hydrolysed by lipases into glycerol and butyric acid (water-soluble).
- the fat-soluble substrate is mixed with the liquid medium or deposited on the agar, the culture medium becomes cloudy.
- the substrate becomes water-soluble following the action of the lipase, this cloudiness of the culture medium disappears in proportion to the hydrolysis.
- Corynebacterium xerosis and Staphylococcus epidermis are important commensal strains of the axillary area. Staphylococcus epidermis is a beneficial probiotic skin strain and Corynebacterium xerosis is the main strain responsible for malodour.
- the Minimal Inhibitory Concentration is the lowest concentration of an antibacterial agent needed to inhibit the visible growth of the strain being tested. The higher the percentage is, the less the tested product has antibacterial activity.
- the culture medium is inoculated with the strains Corynebacterium xerosis and Staphylococcus epidermis , and different percentages of the extract according to the invention or inoculated with a product on the market known for its antibacterial action (Triclosan or Phenonip TM ). Then, the test is incubated for 48 hours at 32.5°C ⁇ 2.5°C. After incubation, the presence or absence of cloudiness is observed, with the presence of cloudiness indicating a bacterial growth.
- MIC Minimal Inhibitory Concentration
- Triclosan and Phenonip TM both preservatives used in cosmetic products, have a very low MIC, respectively 0.013% and 0.63% on S. epidermidis, whereas the extract according to the invention has a MIC greater than 20%.
- Phenonip TM shows a MIC of 0.63% on Corynebacterium xerosis whereas the extract according to the invention has a MIC of 14%.
- the extract according to the invention is a product that respects the microbiome, because a high concentration is needed to obtain an equivalent result of 0.63% of Phenonip TM or 0.013% of Triclosan and alter the two most important microbial strains of the axillary area. Therefore, the extract according to the invention does not alter bacterial growth.
- the intensity of axillary odour is assessed every hour, from 0 to 8 hours after application of a composition comprising 3% of the extract according to the invention or a placebo.
- the study took place over 3 days: the first day for odour cleansing, the second day with the placebo application on one side and the composition comprising 3% of the extract according to the invention on the other side, and the reverse on the third day.
- the smell was assessed every hour and a score was given for each armpit, ranging from 0 to 5: 0 (no pleasant smell), 1 (very slight pleasant smell), 2 (slight pleasant smell), 3 (normal smell), 4 (pleasant smell) and 5 (very pleasant smell).
- composition comprising 3% of the extract according to the invention significantly reduces the bad axillary odour after 8 hours of application (-35.4%; p ⁇ 0.01).
- composition comprising 3% of the extract according to the invention significantly reduces the bad axillary odour after 8 hours of application (-35.4%; p ⁇ 0.01).
- Elastin is an extracellular matrix molecule.
- the elasticity of the skin is modified during aging due to the decrease in the quantity of produced elastin, due to an inappropriate assembly of the elastin fibres.
- the cells as they reached confluency are brought into contact or not (for the control cases) with the extract according to the invention in culture medium, then incubated at 37°C and 5% CO2 for 5 days. After this contact, cell layers are rinsed, fixed, and stained with anti-elastin antibody. The labelling is revealed using a fluorescent secondary antibody and photographs captured under a microscope. Elastin production can be quantified by image analysis on these photographs. A counter-labelling of the nuclei is performed using the fluorescent dye HOESCHT, which marks the DNA, to evaluate the cell population and thus to weight the fluorescence data obtained.
- HOESCHT which marks the DNA
- DEJ assures the cohesion between the dermis and the epidermis. During aging, a decrease of synthesis of its components (especially collagen VII and laminin) is observed. The aging of the DEJ has significant repercussions on the resilience of the skin and the loss of its dynamism.
- HK Human keratinocytes
- HK Human keratinocytes
- the syntheses of collagen VII and laminins are evaluated using ELISA type kits.
- the number of cells is estimated using the Hoechst method and used to standardize the results.
- Collagen VII ( ⁇ g / mL / 10 6 cell.) Variation (%); significance Control 5.8 ⁇ 0.3 Reference 0.26 % of the extract according to the invention 8.5 ⁇ 0.4 + 47 %; p ⁇ 0.01
- the extract according to the invention can improve the aging of the skin linked to a disorganization of the DEJ, by counteracting the loss of suppleness and elasticity that it causes.
- Oxidative stress plays a central role in the cutaneous response to various stresses. Free radicals (H 2 O 2 , OH•, O 2 -, O 2 , 1 O 2 ”) lead to protein, lipid, and DNA damages, causing premature aging of the skin.
- DPPH 2,2-diphenyl-1-picrylhydrazyl
- DPPH-H 2,2-dipheny-1-picrylhydrazine
- O 2 singlet test A system generating O 2 singlet receives the product according to the invention.
- the degradation of uric acid is followed at 292nm by spectrophotometry.
- DDPH Average variation of optical density Variation (%); significance Control 0.268 ⁇ 0.005 Reference 2 % of the extract according to the invention 0.101 ⁇ 0.037 - 62 %; p ⁇ 0.01 3 % of the extract according to the invention 0.082 ⁇ 0.059 - 69 %; p ⁇ 0.01
- the extract according to the invention has a high antioxidant capacity, allowing to effectively combat premature skin ageing.
- Glycation of proteins with reducing sugars in the skin is also responsible for skin aging.
- the study of the non-enzymatic glycation is done between a model protein, the serum albumin, which serves as a target, and an edible reducing sugar from fruits.
- the protein is gradually glycated (bound to sugar) in an irreversible manner, in the presence or not of the product according to the invention. This change is followed by fluorescence.
- Non-enzymatic glycation (Average variation in fluorescence unit) Variation (%); significance Control 84540 ⁇ 1803 Reference 2 % of the extract according to the invention 7926 ⁇ 403 - 92 %; p ⁇ 0.01 3 % of the extract according to the invention 5304 ⁇ 667 - 95 %; p ⁇ 0.01
- the extract according to the invention has anti-glycation capacity that also helps to combat skin ageing.
- An astringent substance able to shrink or tighten body tissues by aggregation, is perfectly adapted to:
- the in tubo assay for determining the astringency capacity of a product is based upon tannin-polymer interaction resulting in the formation of insoluble polymer tannin complexes which then precipitate.
- the difference in optical density (OD) before and after precipitation corresponds to the astringency capacity of the product.
- the extract according to the invention on the one hand, and red wine on the other, are incubated with and without methylcellulose and the optical density at 280nm is measured by spectrophotometer.
- the precipitated part of the extract corresponds to the astringent tannin fraction.
- Tannic red wine is considered as an astringent positive control. Its astringency is of 1334ppm.
- the extract according to the invention shows an astringent capacity that is, statistically different 295% higher than that of tannic red wine.
- the skin has numerous pores on its surface whose function is to evacuate excess sebum and impurities from the skin, such as dead cells and sweat. Oily skin is associated with excessive sebum production by the sebocytes. Too much sebum leads to changes in the properties of the skin and scalp, for example by increasing the formation of pimples and blackheads and clogging pores, which then become dilated and more visible, leading to uneven skin texture and/or excessive growth of the bacteria responsible for dandruff, such as Malassezia fungi on the scalp.
- An anti-seborrheic cosmetic active ingredient will counteract this development by reducing sebum production, which will have the effect of tightening skin pores, smoothing it and reducing the oily/shiny appearance with irregular texture characteristic of oily skin and/or making the scalp healthier, with less dandruff and associated itching.
- Sebocytes are seeded in their growth medium. At confluence, the cells are contacted or not (control case) with the extract according to the invention for 48 hours. After removing media, monolayers are incubated with Nile Red marker of intracellular lipids which estimates the amount of lipids in the cells. The estimate of the viability is performed in parallel on the same layers using a fluorescent dye.
- the extract according to the invention can be used to treat skin disorders associated with oily skin or skin with a tendency to become oily, such as a shiny, glossy appearance and the size and number of pores, to give the skin a smoother, more uniform, more harmonious appearance and/or to make the scalp healthier, with less dandruff and associated itching.
- Human keratinocytes are cultured at sub-confluence and then contacted or not (for the control cases) with the extract according to the invention. After this contact, the synthesis of hyaluronic acid is assayed using ELISA methods. The cell concentration is estimated using the Hoechst method.
- Hyaluronic acid ( ⁇ g / mL / 10 6 cell.) Variation (%); significance Control 340 ⁇ 37 Reference 0.26 % of the extract according to the invention 1215 ⁇ 106 + 257; p ⁇ 0.01
- Human keratinocytes are cultured at sub-confluence and then contacted or not (for the control cases) with the extract according to the invention. Differentiation is monitored visually by observing the phenotype of the keratinocytes over 4 days.
- the untreated cells show a layer of contiguous keratinocytes with well-marked cell outlines, whereas in the presence of 3% of the product according to the invention, the cells shrink and the contacts between the cells decreases until there are empty spaces between the cells, an aspect characteristic of advanced differentiation of keratinocytes.
- the extract according to the invention increases keratinocyte differentiation, helping to protect the epidermis and improve hydration.
- Inflammatory mediators are very present in micro-inflammatory phenomena. Reducing the presence of these mediators has the effect of decreasing sensations of discomfort and redness in sensitive skin.
- NHDF Normal Human Dermal Fibroblasts
- the extract according to the invention strongly and significantly reduces both pro-inflammatory messengers.
- the extract according to the invention reduces skin micro-inflammations.
- the extract according to the invention can therefore be used to soothe the cutaneous discomforts of sensitive skin such as redness, tightness, etc.
- Undesirable skin effects such as sensitive or dry skin, redness, tightness, acne, increased sweating and/or the appearance of unpleasant odours, may be linked to intrinsic, psychological factors such as stress or a hormonal factor, or extrinsic factors such as a reduction in quality of life.
- Emotions result from communication between the neurons in our brain. This communication induces brain waves with a frequency of between 1 Hertz and 80 Hertz, with amplitudes of 10 ⁇ V to 100 ⁇ V, which can be recorded by an electroencephalograph using electrodes placed at four points in the prefrontal cortex.
- alpha waves The frequency of these waves is known to be linked to the consumer psychological state. Therefore, they can be used to detect emotional states of mind, more specifically by observing alpha waves (8-12Hz) and beta waves (12-30Hz). It has been shown that alpha waves predominantly appear when the subject is relaxed or at rest, and can therefore be correlated with brain inactivity, and that beta waves appear when the subject is active, and, therefore, can be correlated with excitement, for example intense mental activity or a stress state.
- Cream used for the study cream described in example 4 below vs . placebo cream.
- the placebo cream used is identical to example 4 below, except that it does not contain the extract according to the invention, although it does contain the solvents used for the extract according to the invention.
- the panellists also carried out a sensory evaluation of the cream containing the extract according to the invention vs . placebo. It was found that the creams could not be distinguished sensorially (firmness, stickiness, rigidity, wettability, spreadability, thickness, slipperiness, etc.).
- the classification of emotions can be based on a dimensional model of valence and arousal. Russell's two-dimensional model was used.
- Valence corresponding to the subject's degree of satisfaction and well-being ('pleasant' when positive and 'unpleasant' when negative), and arousal ('excited' when positive and 'calm' when negative) constitute the abscissa and ordinate of the two-dimensional model respectively.
- beta waves are associated with a state of alertness or excitement, while alpha waves are more dominant in a state of relaxation.
- the cream including the extract according to the invention instantly increases the well-being of volunteers by increasing the feeling of happiness and enthusiasm and reducing feelings of annoyance and stress. It also reduces perspiration and the associated unpleasant odours.
- Additional active ingredients acting in support and/or in addition to the activity of the active ingredient according to the invention may be added in the appropriate phase according to their hydrophobic, hydrophilic or amphiphilic nature.
- These ingredients can be of any category according to their function(s), the place of application (scalp, face, body, neck, bust, hands, etc.), the desired end effect and the targeted consumer, for example specific anti-ageing, anti-wrinkle, moisturizing, anti-dark circles, firming, anti-glycation, slimming, volumizing, soothing, myo-relaxing, anti-redness, sensitive skin, anti-stretch marks, detoxifying, mattifying etc.
- Active ingredient according to the invention Sichuan berry extract according to the invention in a water-propylene glycol matrix.
- This ingredient is recommended in a composition at a level of 1 to 5%, preferably 3%. These levels can vary without departing from the scope of the present invention, depending on the more or less pronounced effects sought.
- phase A weigh out phase A and heat.
- phase B homogenise and heat.
- phase C Add phase C to phase B+A, with stirring. Allow to cool.
- phase D add to cooled phase C+B+A, under stirring.
- phase A weigh out phase A and add phase B, under stirring. Add phase C to phase B+A, under stirring. Add phase D to phase C+B+A, under stirring. In a container, add phase E to phase D+C+B+A.
- phase A weigh out phase A and heat to 85°C in a bain-marie.
- phase B weigh out phase B and heat to 85°C in a bain-marie.
- Add phase B to phase A stirring vigorously.
- Weigh phase C and add to phase A+B with stirring.
- Crodarom® Nordic Cotton active ingredient marketed by Crodarom, to help strengthen the skin's barrier function, soothe the most sensitive skin and moisturise and protect the hair.
- Phytessence TM Blue Daisy Ingredient marketed by Crodarom, soothes sensitive skin and reduces feelings of discomfort by acting on the synthesis of inflammation mediators.
- Crodarom® Bamboo Tea EC ingredient marketed by Crodarom, stimulates cellular metabolism while maintaining the skin's moisture level, and protects the skin from external aggression.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
Abstract
The present invention concerns the use of a Sichuan pepper extract and a composition comprising said extract, for a cosmetic and/or dermatological treatment, in particular a topical treatment. The extract according to the invention has moisturising, soothing, anti-ageing, anti-odour, and skin care effects on oily skin, including the scalp, and on acne-prone skin, in particular by acting on the production of various molecules such as hyaluronic acid, elastin, collagen and laminins, and on the inhibition of oxidation, radicals, lipases and inflammation factors, while preserving the skin microbiota.
Description
The present invention relates to the use of an extract of Sichuan pepper, more particularly of berries, and a composition comprising said extract for a cosmetic or dermatological treatment, in particular a topical treatment.
« Cosmetic or cosmeceutical treatment » means a treatment which treats healthy skin and/or skin appendages, said treatment being intended to improve or beautify their appearance and condition. Such treatment has no therapeutic purpose.
The present invention relates in particular to the cosmetic and dermo-pharmaceutical industries, which manufacture and/or use products intended for the treatment of the skin, including the scalp, mucous membranes and appendages (such as hair, eyelashes, eyebrows, nails) of mammals, animals or humans, for improving their appearance and/or their general condition.
These industries are in increasing demand for new products, in particular in demand for new active ingredients which are derived from plants because they offer a combination of efficacy, limitation of risks of irritation and allergy, reduction of side effects and biodegradability with the possibilities of labelling / certification and matching with a logic of sustainable development and/or fair trade.
« Holistic » products appear on the market to enhance the daily skincare routine. The aim is to act on the user's well-being, to deal with its emotions as a whole. The product must give the user a good overall feeling, both in terms of skin beautifying and in terms of sensory and olfactory comfort. Beautifying the skin will typically mean, for example, a smoother skin with less roughness, greater elasticity, less sagging, a more radiant complexion, more homogeneous with fewer imperfections, while sensorial comfort will mean, for example, a smooth touch, a soothing of the skin with less redness and tightness, and olfactory comfort by neutralising or masking body odours.
Human odour is genetically controlled and systematically influenced by gender and ethnicity, along with emotional, physiological and environmental factors (influence of sweat composition and quantity). Body malodour affects social interaction by reducing self-confidence.
Body odour originates from sweat secreted by the sudoriferous glands, which can be of two types:
- Eccrine sweat glands are found mainly on the hands palms and the feet soles. Eccrine sweat is responsible for regulating body temperature.
- Apocrine sweat glands are bigger, confined to shaggy areas, mainly the armpits, perineal area and scalp. Apocrine sweat is responsible for body odour.
The apocrine sweat contains large, odourless, and non-volatile molecules. Odour is generated when these molecules are lysed into small, volatile odorous entities. This lysis is carried out by enzymes including lipases, which are themselves produced by skin bacteria.
To combat odours, most people use antiperspirant or deodorant on a daily basis. Most of these products are antibacterial and/or contain aluminium salts. These products have the ability to tighten the pores of the skin, and therefore reduce the flow of sweat, but have numerous disadvantages, including an increased risk of breast cancer.
The aim of the present invention is to respond to all of these demands, namely to offer a complete cosmetic product and treatment, in particular a "holistic" treatment, and more specifically to respond to the demand for a body odour treatment.
« Body odour treatment » means an anti-odour treatment designed to reduce, mask, eliminate, absorb and/or limit the generation of the bad odour resulting from the decomposition of sweat by bacteria.
For this purpose, the applicant provides the use of a Sichuan berries extract of species Zanthoxylum bungeanum or Zanthoxylum simulans for a non-therapeutic cosmetic treatment of the skin and its appendages. Preferably according to the invention, the treatment is a topical treatment.
« Topical treatment » or « topical use » means according to the invention, an application that is intended to act where it is applied: skin, mucosa and/or appendages.
The Sichuan pepper tree is defined by one of these two species: Zanthoxylum bungeanum and Zanthoxylum simulans. It is from the Sichuan region (China).
The Sichuan pepper tree used according to the invention is preferably Zanthoxylum bungeanum.
It is a thorny and robust shrub of the Rutaceae family, which corresponds to the citrus family. The main ethnobotanical properties attributed to this plant species are the relief of dental problems and gastrointestinal disorders, the effectiveness against rheumatism and its analgesic action. The fruit envelopes of the Sichuan pepper plant are widely used in Japan as a spice for their powerful, aromatic smells and ripe citrus flavors.
Sichuan berries come from the pericarp of the fruit of the Sichuan pepper tree.
In vitro tests results are given below in the description showing beneficial cosmetic activities for the skin and its appendages:
- On the olfactory level, a treatment to reduce body odour by reducing the lipase activity of bacteria, while advantageously preserving the skin microbiota, whereas the majority of products currently on the market are antibacterial. An in vivo olfactory sweat test confirms these results.
- On the skin beautifying or general improvement:
1) an anti-ageing treatment, for a denser, plumper, firmer, softer and more elastic skin with, as a result, a more even and/or smoother skin texture and a more radiant complexion, thanks to the preservation and stimulation of the synthesis of various molecules of the dermal extracellular matrix (ECM), such as:
- elastin, responsible for skin resilience and elasticity, and
- collagen VII and laminins strengthening the dermal-epidermal junction (DEJ), which ensures that keratinocytes are well anchored to the basal layer and that there is a better communication between the cells, leading to a polarisation of the keratinocytes and therefore to a better skin barrier. The barrier is therefore less fragile, which contributes to the flexibility of the epidermis.
- an increase of the anti-radical and antioxidant effect, particularly on the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical and singlet oxygen, and also an anti-glycation effect, helping to preserve the dermal ECM.
The increase in oxidative and radical forms is linked to age and/or repeated environmental stresses, such as UV rays. Radicals and reactive oxygen species attack membrane lipids and/or functional proteins in the dermal ECM, such as collagen and elastin.
Regarding glycation, it also affects proteins and/or reducing sugars. These interactions with proteins and/or reducing sugars alter the mechanical and elastic properties of the dermal ECM, which becomes less flexible, more rigid, but also more flabby and less reactive. Visually, this results in the appearance of fine lines and wrinkles, and a skin that is dull, flaccid, lacking radiance, tired-looking, and lacking tone and suppleness.
2) a treatment of oily and acne-prone skin, by reducing sebum production and/or an astringent action, which together have the effect of reducing the size of pores and making them less visible, reducing the shiny appearance characteristic of oily skin and/or making the scalp healthier, with less dandruff and associated itching.
3) An anti-dandruff scalp treatment, by reducing sebum production and/or the lipase activity of bacteria, while preserving the skin microbiota.
Sebum leads to excessive growth of dandruff-causing bacteria such as Malassezia fungi on the scalp. This fungus is responsible for the formation of dandruff and the itching associated with it.
On the surface of the scalp, Malassezia release lipases to ensure their growth, which hydrolyse triacylglycerols into monoacylglycerols and then into fatty acids and glycerol. These free fatty acids inhibit the growth of other micro-organisms, encourage the proliferation of Malassezia and penetrate the stratum corneum, causing damage to the skin barrier.
4) a moisturising treatment, with an increase in hyaluronic acid synthesis and in keratinocyte differentiation.
Hyaluronic acid is a major constituent of the epidermis contributing to the barrier function as well as to the maintaining of a satisfactory hydration of the skin. It is capable of absorbing 1,000 times its own weight in water. It is in the form of an aqueous and nourishing gel which fills the spaces between the keratinocytes. It prevents from dryness of the skin, which is known to alter the texture of the skin, giving it a rough touch.
The differentiation of the keratinocytes begins from the basal layer of the epidermis. The epidermis is divided into a plurality of layers:
- the deeper layer is the basal layer, comprising keratinocytes, and
- the most superficial layer is the stratum corneum, consisting of a plurality of keratinocyte layers at the terminal stage of their differentiation and called corneocytes. This highly water-insoluble corneal envelope is composed of anucleate corneal cells, without cytoplasmic organelles and completely keratinised.
Keratinocytes migrate from the deeper layer to the most superficial layer, differentiating themselves into corneocytes.
The stratum corneum is a semi-permeable protective layer that prevents water loss and keeps the skin hydrated. It is composed of the corneocytes, lipids and lamellar bodies, and "natural moisturizing factors" (NMF - substances capable of binding water in the stratum corneum) which maintain the level of skin moisture at an optimum level.
The transepidermal water loss (TEWL) characterises the evaporation of water contained in the skin: the more the skin barrier is damaged, the more easily water evaporates.
Improved differentiation of keratinocytes leads to a strengthening of the skin barrier and, as a result, leads to a better protection of the epidermis and improved moisturizing.
- On the sensory level:
A skin soothing treatment, thanks to the reduction of inflammation mediators responsible for the appearance of skin micro-inflammations causing feelings of tightness and discomfort, and also thanks to a moisturizing treatment as described above, resulting in a skin that is softer and less rough.
- On an emotional level:
A cosmetic treatment adapted to improve consumer well-being by increasing feelings of happiness and enthusiasm, and reducing stress and annoyance, as demonstrated by an in vivo test using electroencephalogram (EEG) analysis.
These cosmetic effects can be envisaged according to the invention separately or in combination, making it possible in particular to offer a use of "holistic" type combining olfactory, beautifying, sensorial and emotional effects.
Thus, preferably the present invention provides the use of Sichuan berry extract of the species Zanthoxylum bungeanum or Zanthoxylum simulans, for at least one treatment selected from:
- a body odour treatment; and/or
- a treatment of oily and acne prone skins; and/or
- an anti-ageing treatment; and/or
- a moisturizing treatment; and/or
- a soothing treatment.
According to other preferred features, the extract of Sichuan berries, of the species Zanthoxylum bungeanum or Zanthoxylum simulans, used according to the invention can be obtained by the usual solid/liquid extraction techniques including, for example, maceration, simple decoction, infusion, leaching, extraction under reflux, extraction by subcritical or supercritical fluid, extraction by means of ultrasound or microwaves or any other physical and/or chemical method, such as percolation, digestion, cryoextraction, enzymatic digestion, etc.
Preferably according to the invention, the extract is obtained by extraction under reflux, maceration, decoction, infusion, leaching, extraction by subcritical or supercritical fluid, extraction by means of ultrasound or microwaves, percolation, digestion, cryoextraction, or enzymatic digestion.
« Maceration » means a process consisting of soaking a plant or part of a plant in an extraction solvent at room temperature.
« Infusion » means a process consisting of bringing the extraction solvent to the boil before pouring it onto the plant or part of the plant.
« Decoction » means a process consisting of blending the plant or the part of plant with the extraction solvent, then heating the mixture at the boiling point.
« Digestion » means a process consisting of blending the plant or the part of plant with the extraction solvent, then heating the mixture below boiling point.
Preferably, according to the invention, the extract is obtained by digestion of Sichuan berries in at least one aqueous, alcoholic, hydroalcoholic, glycolic or lipidic solvent or mixture thereof, such as water, a C1, C2, C3 or C4 alcohol, or a polyol selected from pentanediol, sorbitol, butylene glycol, pentylene glycol, propylene glycol, hexanol, caprylic/capric triglyceride (GTCC), a vegetable oil, or a mixture thereof.
Preferably, the extraction solvent is a glycolic solvent, and more preferably, the propylene glycol.
The extract of Sichuan berry, Zanthoxylum bungeanum or Zanthoxylum simulans, used according to the invention comprises as main components xanthoxylin, polyphenols including flavonoids, carbohydrates, and proteins.
This extract can be used as it is or in a composition, diluted in a physiologically acceptable medium. The nature of the medium is defined as a function of the properties of the Sichuan berry extract, and also as a function of the destination of the composition formed: simple ingredient, more sophisticated galenic form of a final composition for the consumer.
"Physiologically acceptable medium" means according to the present invention, without limitation, an aqueous or hydro-alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a micro-emulsion, an aqueous gel, an anhydrous gel, a serum, a dispersion of vesicles, or a powder.
"Physiologically acceptable" means that the compositions are suitable for topical or transdermal use, in contact with mucous membranes, appendages (nails, hair and body hair), scalp and skin of mammals, particularly human, compositions which may be ingested, or injected into the skin, without risk of toxicity, incompatibility, instability, allergic response, and others. This "physiologically acceptable medium" forms what is commonly called the excipient of the composition.
According to the invention, the physiologically acceptable medium can be an aqueous, hydroglycolic or hydroalcoholic solution, or a water-in-oil emulsion, an oil-in-water emulsion, or a microemulsion. Preferably, it is hydroglycolic. Preferably, the physiologically acceptable medium is a blend of propylene glycol and water.
Therefore, the present invention covers a non-therapeutic, cosmetic or nutraceutical topical treatment method for beautifying or improving the appearance and general condition of skin and/or its appendages, and for treating their imperfections, by applying in a subject in need thereof an effective amount of at least one Sichuan berry extract according to the invention or a composition comprising it, in a physiologically acceptable medium.
The effective amount of Sichuan berry extract according to the invention, that is to say its dosage, depends on the destination of the composition. It depends on various factors, such as the age, the condition of the patient, the severity of the disorder and the administration mode. An effective amount means a non-toxic amount enough to achieve the desired effect.
In a cosmetic composition according to the invention containing at least a Sichuan berry extract, to be present in an effective amount, it is generally present in an amount ranging from 0.000001% and 15% based on the total weight of the composition, preferably ranging from 0.00001% and 10%, depending on the destination of the composition and the more or less pronounced desired effect. More preferably, the effective amount is between 0.0001% and 5% based on the total weight of the composition.
All percentages and ratios used herein are by weight of the total composition and all measurements are made at 25°C unless it is otherwise specified.
According to other features, the cosmetic treatment method according to the invention can be combined with one or more other treatment methods targeting the skin such as luminotherapy, heat or aromatherapy treatments.
Devices with several compartments or kits may be proposed to apply the method described above which may include for example and non-restrictively, a first compartment containing a composition comprising the Sichuan berry extract of the invention, and in a second compartment an additional active ingredient, the compositions contained in the said first and second compartments in this case being considered to be a combination composition for simultaneous, separate or stepwise use in time, particularly in one of the treatment methods recited above.
For indication, for a cosmetic face treatment, the European standard dosage of a cream is 2.72 mg/cm²/day/person and for a cosmetic body treatment the European standard dosage of a lotion is 0.5 mg/cm²/day/person.
According to other advantageous features, the Sichuan berry extract according to the invention may be associated with one or more other active ingredients at effective concentrations that can act synergistically or additionally for reinforcing and achieving the desired effects described for the invention, such as the following agents: filtering radiations, in particular UVA, UVB, IR or generated by blue light, hydrating, moisturizing, humectant, calming, muscle relaxant, slimming, restructuring, firming, replumping, lifting, smoothing, acting on blood microcirculation, inflammation, free radicals, anti-aging, anti-fine lines and wrinkles, lightening, acting on complexion, anti-glycation, anti-carbonylation, pro- pigmenting, acting on stratum corneum, on dermal -epidermal junction, on HSP protein production, on firmness, elasticity and tone of skin, on hair growth or anti-regrowth (including eyelashes and eyebrows), on eye contours (dark circles and under eye bags), peptides, vitamins, etc. These active ingredients can be obtained from plant materials, such as plant extracts or products of plant culture or fermentation production methods.
The Personal Care Products Council ("International cosmetic ingredient dictionary & handbook" published by the "Cosmetic, Toiletry, and Fragrance Association, Inc.", Washington, D.C.) describes a non-limited wide variety of cosmetic and pharmaceutical ingredients conventionally used in the skin care industry that can be used as additional ingredients in the compositions for the present invention, as long as they are physically and chemically compatible with the other ingredients of the composition and especially with the active ingredients of the present invention. Also, the nature of these additional ingredients should not unacceptably alter the benefits of the active ingredient of the invention. These additional ingredients can be synthetic or natural such as plants extracts or issued from a bio-fermentation process.
Further skin care actives that are particularly useful combined with the composition can be found in Sederma's commercial literature and on the website www.sederma.fr, in Croda's commercial literature and on the website www.croda.fr.
More specifically, the Sichuan berry extract according to the invention can be combined with at least one compound chosen among vitamin compounds, group B C, E, F, D and A, especially compounds as niacinamide or tocopherol, retinoids compounds as retinol, hyaluronic acid, hexamidine, α-lipoic acid, resveratrol or DHEA, peptides, aluminium salts, phosphate salts, magnesium oxide, zirconium hydrochloride salts, ceramides, which are classic active ingredients used in topical cosmetic or dermo-pharmaceutical compositions.
Furthermore, the present invention provides the use of a Sichuan berries extract of species Zanthoxylum bungeanum or Zanthoxylum simulans, as described above, for the manufacture of a composition for a cosmetic treatment, as described above.
The composition for the use according to the invention can be provided in any galenic form (examples are given below) defined according to the composition destination and application site.
A composition according to the invention can be applied to the face, body, neckline, scalp, hair, eyelashes, body hair, in any form or vehicle known to those skilled in the art, in particular in the form of a solution, dispersion, emulsion, paste or powder, individually or as a premix or vehicle individually or as a premix in a bound form, incorporated or adsorbed in vectors such as macro-, micro-, or nanocapsules, macro-, micro- or , nanospheres, liposomes, oleosomes or chylomicrons, macro-, micro-, or nanoparticles or macro-, micro or nanosponges, micro- or nanoemulsions, or adsorbed on organic polymer powders, talcs, bentonites, spores or exines, and other inorganic or organic supports.
In cosmetics, applications can be proposed in particular in the ranges of skin care for the face, body, hair and body hair and ranges of make-up treatments, in particular eyelashes and eyebrows.
For example, the galenic form of the composition can be a lotion, a cream, a butter, a milk, a solid form, a foam, a gel, a deodorant, an antiperspirant, a shampoo, a conditioner, a hair mask, a face mask, a shower gel, etc.
Also for example, in the case of an anti-odour use, the galenic form of the composition can be a cream for the face, the feet, and/or the whole body, a spray, an aerosol, a roll-on or a deodorant stick. For an « holistic » product, the preferred galenic form may be a body lotion.
The galenical formulations can enter in different product ranges for personal care and/or beauty products including skin care, cleaning, makeup, cleansing, sunscreen, artificial tanning, pre-shave, shaving or aftershave, moisturizer, humectant, emollient, conditioning, exfoliating, astringent, depilatories or antiperspirant, deodorant, etc.
The composition may be incorporated onto a non-woven or woven material, with natural or synthetic fibres, wool, or any material intended to come into contact with skin and that can be used in clothing, including tights and socks, shorty, day or night underwear, tissues, handkerchiefs or fabric to exert its cosmetic effect via the contact skin/textile and enable continuous topical delivery (cosmetic-textiles).
According to the invention, it is thus also provided a woven or non-woven fabric comprising at least one a Sichuan berry extract, for use in a non-therapeutical cosmetic treatment.
The present invention will be better understood in the light of the following description of an embodiment, the in vitro tests and figures described below.
- Figure description
- Examples of obtaining a Sichuan berry extract according to the invention and a composition comprising it
Plant material: Sichuan berries of the species Zanthoxylum bungeanum.
Maceration solvent: Propylene glycol
Protocol: berries are macerated in propylene glycol for 1 to 6 hours at 70 to 100°C, then the macerate is filtered to remove solid plant debris. Several successive filtrations are carried out, with a size of between 5 and 0.1µm. The filtered macerate constitutes the berry extract according to the invention. Advantageously, according to this method a xanthoxylin-rich extract of Sichuan berries is obtained, with a xanthoxylin content of between 10 and 20% by weight based on the weight of the dry extract. This molecule is identified by high-performance thin-layer chromatography (HPTLC).
To obtain a composition comprising the extract according to the invention, the filtered macerate obtained is mixed with a physiologically acceptable matrix consisting of a water-propylene glycol mixture. The ratio of water to propylene glycol in the composition is between 0:100 and 30:70.
- Evaluation of the various activities of the extract according to the invention, by in vitro and in vivo tests
- Body odours
- Lipase activity
- Body odours
Lipases are able to hydrolyse triglycerides having long fatty acid chains into glycerol and the corresponding volatile fatty acids responsible for unpleasant odour.
Lipases are widely distributed in bacteria, yeasts and filamentous fungi. They are produced by Gram-positive bacteria such as Corynebacterium, Propionibacterium, Cutibacterium and Staphylococcus, as well as Gram-negative bacteria such as Pseudomonas.
In the axillae area, the genus Corynebacterium is mainly responsible for axillary malodour. Gram-negative bacteria bring almost no contribution to axillary malodour.
Glycerol tributyrate substrate (fat-soluble) is hydrolysed by lipases into glycerol and butyric acid (water-soluble). When the fat-soluble substrate is mixed with the liquid medium or deposited on the agar, the culture medium becomes cloudy. When the substrate becomes water-soluble following the action of the lipase, this cloudiness of the culture medium disappears in proportion to the hydrolysis.
Two methods are used to demonstrate the anti-lipase activity of the extract according to the invention:
- a method in liquid medium for which the cloudiness is measured at 620nm by spectrophotometry.
- a method on an agar plate, for which the cloudiness is assessed visually.
- Analysis in liquid medium
Evolution of the lipase activity of Corynebacterium xerosis over time. Effect of a composition comprising 3% of the extract according to the invention compared to the control (n=3):
Control | 3% of the extract according to the invention | Variation (%); significance | |
0 hour | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.0 %; nsd* |
48 hours | 57.00 ± 0.06 | 43.70 ± 1.31 | - 23.3 %; p<0.0001 |
72 hours | 77.40 ± 0.19 | 40.50 ± 0.20 | - 47.7 %; p<0.0001 |
*nsd: non-significant data
These results show that 3% of the extract according to the invention significantly reduces the lipase activity of Corynebacterium xerosis at 48 hours (- 23.3%; p<0.0001) and 72 hours (-47.7 %; p<0.0001).
- Analysis in agar medium
By comparing these two figures, we can see that the cloudiness is less present in the agar medium containing 3% of the extract according to the invention than in the control case, which means that the glyceryl tributyrate has been hydrolysed to a greater extent and that the extract according to the invention therefore reduces the lipase activity of Corynebacterium xerosis under the test conditions.
Both methods, in liquid and in agar medium, demonstrate that the lipase activity of Corynebacterium xerosis decreases in contact with the extract according to the invention.
- Protection of bacterial flora
Corynebacterium xerosis and Staphylococcus epidermis are important commensal strains of the axillary area. Staphylococcus epidermis is a beneficial probiotic skin strain and Corynebacterium xerosis is the main strain responsible for malodour.
The Minimal Inhibitory Concentration (MIC) is the lowest concentration of an antibacterial agent needed to inhibit the visible growth of the strain being tested. The higher the percentage is, the less the tested product has antibacterial activity.
The culture medium is inoculated with the strains Corynebacterium xerosis and Staphylococcus epidermis, and different percentages of the extract according to the invention or inoculated with a product on the market known for its antibacterial action (Triclosan or PhenonipTM). Then, the test is incubated for 48 hours at 32.5°C ± 2.5°C. After incubation, the presence or absence of cloudiness is observed, with the presence of cloudiness indicating a bacterial growth.
Minimal Inhibitory Concentration (MIC) of the extract according to the invention, compared to two products on the market (n=3).
MIC | |
Extract according to the invention | |
Corynebacterium xerosis | 14% |
S.epidermidis | > 20 % |
Triclosan | |
Corynebacterium xerosis | > 0.05% |
S.epidermidis | 0.013% |
PhenonipTM (Phenoxyethanol (and) Methylparaben (and) Ethylparaben (and) Propylparaben (and) Butylparaben (and) Isobutylparaben) | |
Corynebacterium xerosis | 0.63% |
S.epidermidis | 0.63% |
These results show that Triclosan and PhenonipTM, both preservatives used in cosmetic products, have a very low MIC, respectively 0.013% and 0.63% on S. epidermidis, whereas the extract according to the invention has a MIC greater than 20%.
In the same way, PhenonipTM shows a MIC of 0.63% on Corynebacterium xerosis whereas the extract according to the invention has a MIC of 14%.
Therefore, the extract according to the invention is a product that respects the microbiome, because a high concentration is needed to obtain an equivalent result of 0.63% of PhenonipTM or 0.013% of Triclosan and alter the two most important microbial strains of the axillary area. Therefore, the extract according to the invention does not alter bacterial growth.
- In vivo olfactory evaluation of sweat
The study was carried out on 14 volunteers: 3 men and 11 women. Among the panellists 5 experts took part in the study. They are trained and experienced to odour and perfume evaluation.
The intensity of axillary odour is assessed every hour, from 0 to 8 hours after application of a composition comprising 3% of the extract according to the invention or a placebo. The study took place over 3 days: the first day for odour cleansing, the second day with the placebo application on one side and the composition comprising 3% of the extract according to the invention on the other side, and the reverse on the third day.
Volunteers were asked, one day before the trial and until the end of the third day, not to eat spicy foods, onions, or garlic, and not to use scented products.
Once the product had been applied, the smell was assessed every hour and a score was given for each armpit, ranging from 0 to 5: 0 (no pleasant smell), 1 (very slight pleasant smell), 2 (slight pleasant smell), 3 (normal smell), 4 (pleasant smell) and 5 (very pleasant smell).
Variation of odour intensity depending on time. Effect of a composition containing 3% of the extract according to the invention compared to the same composition without the extract according to the invention (placebo):
Panel of volunteers (mean) | Expert panel (mean) | |||
T= 0 hour | T = 8 hours | T= 0 hour | T = 8 hours | |
Placebo | 4.7 ± 0.55 | 1.7 ± 0.71 | 4.5 ± 0.53 | 2.1 ± 0.53 |
3% of the extract according to the invention | 4.9 ± 0.31 | 2.3 ± 0.94 | 5.0 ± 0.00 | 3.3 ± 0.00 |
Variation (%); significance | - 4.6 %; p <0.01 | - 35.4 %; p <0.01 | - 11.1 %; p <0.01 | - 57.1 %; p <0.01 |
These results show that for the panel of volunteers, the composition comprising 3% of the extract according to the invention significantly reduces the bad axillary odour after 8 hours of application (-35.4%; p<0.01).
These results show that for the expert panel, the composition comprising 3% of the extract according to the invention significantly reduces the bad axillary odour after 8 hours of application (-35.4%; p<0.01).
These results show that the extract according to the invention decreases body odour in the axilla area.
- Anti-ageing
- Elastin synthesis
Elastin is an extracellular matrix molecule. The elasticity of the skin is modified during aging due to the decrease in the quantity of produced elastin, due to an inappropriate assembly of the elastin fibres.
The cells as they reached confluency, are brought into contact or not (for the control cases) with the extract according to the invention in culture medium, then incubated at 37°C and 5% CO2 for 5 days. After this contact, cell layers are rinsed, fixed, and stained with anti-elastin antibody. The labelling is revealed using a fluorescent secondary antibody and photographs captured under a microscope. Elastin production can be quantified by image analysis on these photographs. A counter-labelling of the nuclei is performed using the fluorescent dye HOESCHT, which marks the DNA, to evaluate the cell population and thus to weight the fluorescence data obtained.
Variation of elastin production by fibroblasts. Effect of the extract according to the invention at 0.14% compared to the control (n = 3):
Elastin (Mean area / number of cells) |
Variation (%); significance | |
Control | 103 ± 17 | Reference |
0.14% of the extract according to the invention | 249 ± 13 | + 141 %; p<0.01 |
These results show that 0.14% of the extract according to the invention significantly increases by 141% (p<0.01) the production of elastin by fibroblasts.
- Strengthening of the dermo-epidermal junction
DEJ assures the cohesion between the dermis and the epidermis. During aging, a decrease of synthesis of its components (especially collagen VII and laminin) is observed. The aging of the DEJ has significant repercussions on the resilience of the skin and the loss of its dynamism.
Human keratinocytes (HK) were cultured at sub-confluence and were brought into contact or not (for the control cases) with the extract according to the invention. After this contact, the syntheses of collagen VII and laminins are evaluated using ELISA type kits. The number of cells is estimated using the Hoechst method and used to standardize the results.
Variation of collagen VII production by keratinocytes. Effect of the extract according to the invention at 0.26% compared to the control (n = 5):
Collagen VII (µg / mL / 106 cell.) |
Variation (%); significance | |
Control | 5.8 ± 0.3 | Reference |
0.26 % of the extract according to the invention | 8.5 ± 0.4 | + 47 %; p<0.01 |
These results show that 0.26% of the extract according to the invention significantly increases by 47% (p<0.01) the production of collagen VII by keratinocytes.
Variation of laminins production by keratinocytes. Effect of the extract according to the invention at 0.26% compared to the control (n = 5):
Laminin (µg / mL / 106 cell.) |
Variation (%); significance | |
Control | 32 ± 2 | Reference |
0.26 % of the extract according to the invention | 51 ± 3 | + 58 %; p<0.01 |
These results show that 0.26% of the extract according to the invention significantly increases by 58% (p<0.01) the production of laminins by keratinocytes.
These results show that the extract according to the invention has a direct action of strengthening the DEJ by stimulating the synthesis of laminins and collagens VII.
The extract according to the invention can improve the aging of the skin linked to a disorganization of the DEJ, by counteracting the loss of suppleness and elasticity that it causes.
- Antioxidant capacity
Oxidative stress plays a central role in the cutaneous response to various stresses. Free radicals (H2O2, OH•, O2-, O2, 1O2 …) lead to protein, lipid, and DNA damages, causing premature aging of the skin.
For the DPPH test: DPPH (2,2-diphenyl-1-picrylhydrazyl) is a stable free radical which is widely used for the detection of free radical scavengers. This molecule while losing its radical character is converted into DPPH-H (2,2-dipheny-1-picrylhydrazine). This conversion is accompanied by discoloration by oxidation-reduction, from violet to yellow, which can be followed in time by spectrophotometry at 490nm.
For the O2 singlet test: A system generating O2 singlet receives the product according to the invention. The degradation of uric acid is followed at 292nm by spectrophotometry.
Variation of DDPH production (n=6). Effect of 2 or 3% of the extract according to the invention compared to the control:
DDPH (Average variation of optical density) |
Variation (%); significance | |
Control | 0.268 ± 0.005 | Reference |
2 % of the extract according to the invention | 0.101 ± 0.037 | - 62 %; p<0.01 |
3 % of the extract according to the invention | 0.082 ± 0.059 | - 69 %; p<0.01 |
These results show that the extract according to the invention significantly decreases the presence of DPPH.
Variation in singlet O2 production (n=2). Effect of 2 or 3% of the extract according to the invention compared to the control:
Singlet O2 (Average variation of optical density) |
Variation (%); significance | |
Control | 32.33 ± 0.81 | Reference |
2 % of the extract according to the invention | 20.02 ± 0.95 | - 38 %; p<0.01 |
3 % of the extract according to the invention | 14.87 ± 1.49 | - 54 %; p<0.01 |
These results show that the extract according to the invention significantly decreases the presence of singlet O2.
The extract according to the invention has a high antioxidant capacity, allowing to effectively combat premature skin ageing.
- Non-enzymatic glycation of BSA
Glycation of proteins with reducing sugars in the skin is also responsible for skin aging.
The formation of many glycated proteins whose functional, enzymatic, structural properties are altered, has consequences on the correct functioning of the cell or the organism.
The consequence is the altering of the mechanical and elastic properties of the extracellular matrix of the dermis, which becomes less flexible, more rigid, but also more flaccid and less reactive, also resulting in a dull complexion.
The study of the non-enzymatic glycation is done between a model protein, the serum albumin, which serves as a target, and an edible reducing sugar from fruits. The protein is gradually glycated (bound to sugar) in an irreversible manner, in the presence or not of the product according to the invention. This change is followed by fluorescence.
Variation of glycation (n=2). Effect of 2 or 3% of the extract according to the compared to the control:
Non-enzymatic glycation (Average variation in fluorescence unit) |
Variation (%); significance | |
Control | 84540 ± 1803 | Reference |
2 % of the extract according to the invention | 7926 ± 403 | - 92 %; p<0.01 |
3 % of the extract according to the invention | 5304 ± 667 | - 95 %; p<0.01 |
The results show the strong anti-glycant potential of the extract according to the invention.
The extract according to the invention has anti-glycation capacity that also helps to combat skin ageing.
- Oily and/or acne prone skins
- Astringency
An astringent substance, able to shrink or tighten body tissues by aggregation, is perfectly adapted to:
- Tighten enlarged pores and reduce excessive oil and sweat secretion;
- Remove sebum excess;
- Precipitate amino acids causing body malodour. These amino acids are formed from corneocytes, secreted proteins or free amino acids generated by bacterial catabolism.
The in tubo assay for determining the astringency capacity of a product is based upon tannin-polymer interaction resulting in the formation of insoluble polymer tannin complexes which then precipitate. The difference in optical density (OD) before and after precipitation corresponds to the astringency capacity of the product.
The extract according to the invention on the one hand, and red wine on the other, are incubated with and without methylcellulose and the optical density at 280nm is measured by spectrophotometer. The precipitated part of the extract corresponds to the astringent tannin fraction.
Astringency of the extract according to the invention compared to red wine (n=4 for the extract according of the invention and n=12 for red wine):
Means Tannins precipitated with Methylcellulose (MCP) (ppm epicatechin equivalent) | % Variation | |
Tannic red wine | 1 334 ±222 | Reference |
Extract according to the invention | 5 276 ± 161 | 295%* |
Tannic red wine is considered as an astringent positive control. Its astringency is of 1334ppm. The extract according to the invention shows an astringent capacity that is, statistically different 295% higher than that of tannic red wine.
- Anti-seborrheic
The skin has numerous pores on its surface whose function is to evacuate excess sebum and impurities from the skin, such as dead cells and sweat. Oily skin is associated with excessive sebum production by the sebocytes. Too much sebum leads to changes in the properties of the skin and scalp, for example by increasing the formation of pimples and blackheads and clogging pores, which then become dilated and more visible, leading to uneven skin texture and/or excessive growth of the bacteria responsible for dandruff, such as Malassezia fungi on the scalp.
An anti-seborrheic cosmetic active ingredient will counteract this development by reducing sebum production, which will have the effect of tightening skin pores, smoothing it and reducing the oily/shiny appearance with irregular texture characteristic of oily skin and/or making the scalp healthier, with less dandruff and associated itching.
Sebocytes are seeded in their growth medium. At confluence, the cells are contacted or not (control case) with the extract according to the invention for 48 hours. After removing media, monolayers are incubated with Nile Red marker of intracellular lipids which estimates the amount of lipids in the cells. The estimate of the viability is performed in parallel on the same layers using a fluorescent dye.
Variation of lipidic synthesis by sebocytes. Effect of the extract according to the invention at 2% compared to the control (n=2):
(UFA/106cell) | Variation (%); significance | |
Control | 160962 ± 6691 | Reference |
2 % of the extract according to the invention | 77026 ± 5163 | - 52%; p<0.01 |
These results show that exposing sebocytes to 2% of the extract according to the invention reduces the quantity of lipids in sebum-producing cells.
The extract according to the invention can be used to treat skin disorders associated with oily skin or skin with a tendency to become oily, such as a shiny, glossy appearance and the size and number of pores, to give the skin a smoother, more uniform, more harmonious appearance and/or to make the scalp healthier, with less dandruff and associated itching.
- Skin hydrating
- Hyaluronic acid synthesis
Human keratinocytes are cultured at sub-confluence and then contacted or not (for the control cases) with the extract according to the invention. After this contact, the synthesis of hyaluronic acid is assayed using ELISA methods. The cell concentration is estimated using the Hoechst method.
Variation of hyaluronic acid production by keratinocytes. Effect of the extract according to the invention at 0.26% compared to the control (n=5):
Hyaluronic acid (µg / mL / 106 cell.) |
Variation (%); significance | |
Control | 340 ± 37 | Reference |
0.26 % of the extract according to the invention | 1215 ± 106 | + 257; p<0.01 |
These results show that the extract according to the invention significantly increases hyaluronic acid synthesis by keratinocytes.
- Keratinocytes differentiation
Human keratinocytes are cultured at sub-confluence and then contacted or not (for the control cases) with the extract according to the invention. Differentiation is monitored visually by observing the phenotype of the keratinocytes over 4 days.
Condition | Pro-differentiation effect observed after 4 days |
Control | 0 |
3% of the product according to the invention | ++ |
Visually, in the control case, the untreated cells show a layer of contiguous keratinocytes with well-marked cell outlines, whereas in the presence of 3% of the product according to the invention, the cells shrink and the contacts between the cells decreases until there are empty spaces between the cells, an aspect characteristic of advanced differentiation of keratinocytes.
The extract according to the invention increases keratinocyte differentiation, helping to protect the epidermis and improve hydration.
- Soothing skin
Inflammatory mediators are very present in micro-inflammatory phenomena. Reducing the presence of these mediators has the effect of decreasing sensations of discomfort and redness in sensitive skin.
Normal Human Dermal Fibroblasts (NHDF) are cultured at confluence. At this stage, they are, contacted with the products to test for 24 hours. After this contact period, the cells are irradiated with UVB, and the cells are then contacted with the products to test for another 24-hour period. The quantities of PGE2 and IL-6 synthesized are measured in the culture supernatants by ELISA assay. The number of cells is assessed in order to normalize the data. An analysis of variance and a Student t-test for non-paired series are performed to evaluate the significance of the results.
Variation of IL-6 and PGE2 production by fibroblasts. Effect of the extract according to the invention at 3% compared to the control (n=3):
IL-6 (pg/106 cell) | PGE2 (pg/106 cell) | ||
Not irradiated | Control | 1244 ± 32 | 1613 ± 49 |
3 % of the extract according to the invention | 627 ± 54 | 334 ± 35 | |
Variation (%); significance | -50 %; p<0.01 | -79 %; p<0.01 | |
Irradiated with UVB | Control | 9238 ± 323 | 8539 ± 683 |
3 % of the extract according to the invention | 3399 ± 181 | 1053± 208 | |
Variation (%); significance | -63 %; p<0.01 | - 88 %; p<0.01 |
Thus, advantageously, the extract according to the invention strongly and significantly reduces both pro-inflammatory messengers.
These results show that the extract according to the invention reduces skin micro-inflammations. The extract according to the invention can therefore be used to soothe the cutaneous discomforts of sensitive skin such as redness, tightness, etc.
- In vivo assessment of improved well-being using EEG analysis
A lot of research shows that the beauty and quality of the skin are closely linked to emotional well-being, and conversely, emotional well-being is improved when people are satisfied with the beauty and quality of their skin.
Undesirable skin effects, such as sensitive or dry skin, redness, tightness, acne, increased sweating and/or the appearance of unpleasant odours, may be linked to intrinsic, psychological factors such as stress or a hormonal factor, or extrinsic factors such as a reduction in quality of life.
For a “holistic” approach to wellness body care, it is interesting to positively boost the user emotions through the application of a care product.
Emotions result from communication between the neurons in our brain. This communication induces brain waves with a frequency of between 1 Hertz and 80 Hertz, with amplitudes of 10µV to 100µV, which can be recorded by an electroencephalograph using electrodes placed at four points in the prefrontal cortex.
The frequency of these waves is known to be linked to the consumer psychological state. Therefore, they can be used to detect emotional states of mind, more specifically by observing alpha waves (8-12Hz) and beta waves (12-30Hz). It has been shown that alpha waves predominantly appear when the subject is relaxed or at rest, and can therefore be correlated with brain inactivity, and that beta waves appear when the subject is active, and, therefore, can be correlated with excitement, for example intense mental activity or a stress state.
The study was carried out on 13 healthy volunteers aged over 18 years old: 2 males and 11 females. Unlike the in vivo olfactory test described above, the panellists were not trained or accustomed to carrying out this type of test.
The study was carried out in 5 stages:
- 2 hours before the start of the session, panellists are asked to wash their forearms with gentle soap.
- The panellists are asked to relax in order to obtain a quality EEG.
- The EEG recording is started before the cream is applied. The panellists must apply the cream until it is absorbed by the skin.
- Then, the panellists are asked to stroke the cream application site.
- The recording is stopped.
As odours are known to influence emotions by recalling memories, it is requested not to smell the product before, during or after the application in order not to distort the EEG results.
Cream used for the study: cream described in example 4 below vs. placebo cream. The placebo cream used is identical to example 4 below, except that it does not contain the extract according to the invention, although it does contain the solvents used for the extract according to the invention.
The panellists also carried out a sensory evaluation of the cream containing the extract according to the invention vs. placebo. It was found that the creams could not be distinguished sensorially (firmness, stickiness, rigidity, wettability, spreadability, thickness, slipperiness, etc.).
Both analysis (EEG and sensory evaluation) were not carried out on the same day.
The classification of emotions can be based on a dimensional model of valence and arousal. Russell's two-dimensional model was used.
Valence, corresponding to the subject's degree of satisfaction and well-being ('pleasant' when positive and 'unpleasant' when negative), and arousal ('excited' when positive and 'calm' when negative) constitute the abscissa and ordinate of the two-dimensional model respectively.
To determine valence, the difference in the ratio of alpha/beta waves between the two cortical hemispheres is calculated. It has been shown that left frontal inactivation is often linked to a negative emotion and right frontal inactivation to a positive emotion.
To determine arousal, the ratio of beta to alpha waves is calculated. As indicated above, beta waves are associated with a state of alertness or excitement, while alpha waves are more dominant in a state of relaxation.
Russell's two-dimensional model is divided into 4 parts:
- Q1, when valence is higher than -0.006 and arousal is higher than 0.914. The corresponding emotions are happiness, excitement, euphoria, or joy.
-. Q2, when valence is higher than -0.006 and arousal is lower than 0.914. The corresponding emotions are satisfaction, concentration, comfort, relaxation, or calmness.
- Q3, when valence is lower than -0.006 and arousal is less than 0.914. The corresponding emotions are drowsiness or boredom.
- Q4, when valence is lower than -0.006 and arousal is higher than 0.914. The corresponding emotions are stress, annoyance, or nervousness.
Variation of valence and arousal. Effect of the cream including 2% of the extract according to the invention compared to the placebo cream:
Average valence | Average activation | Parts of Russell's circular model | |
Placebo cream | -0.0180 | 0.917 | Q4 |
Cream containing the extract according to the invention | -0.0049 | 0.915 | Q1 |
These results show that the cream including the extract according to the invention increases valence and decreases arousal compared to the placebo cream. This means that valence evolves towards more pleasant emotions and arousal evolves towards calmer emotions.
The cream including the extract according to the invention instantly increases the well-being of volunteers by increasing the feeling of happiness and enthusiasm and reducing feelings of annoyance and stress. It also reduces perspiration and the associated unpleasant odours.
- Example of a galenic formulation
Various cosmetic formulations are described below, including the extract according to the invention, in particular as formulated in the active ingredient described in point B. above.
Additional active ingredients, acting in support and/or in addition to the activity of the active ingredient according to the invention may be added in the appropriate phase according to their hydrophobic, hydrophilic or amphiphilic nature. These ingredients can be of any category according to their function(s), the place of application (scalp, face, body, neck, bust, hands, etc.), the desired end effect and the targeted consumer, for example specific anti-ageing, anti-wrinkle, moisturizing, anti-dark circles, firming, anti-glycation, slimming, volumizing, soothing, myo-relaxing, anti-redness, sensitive skin, anti-stretch marks, detoxifying, mattifying etc.
Active ingredient according to the invention: Sichuan berry extract according to the invention in a water-propylene glycol matrix.
This ingredient is recommended in a composition at a level of 1 to 5%, preferably 3%. These levels can vary without departing from the scope of the present invention, depending on the more or less pronounced effects sought.
Raw materials | % | INCI name |
Phase A | ||
SP CITHROL GMS 40 MBAL | 3.9 | Glyceryl stearate |
SP CRODACOL C90 MBAL | 1.9 | Cetyl Alcohol |
SP BRIJ CS12 MBAL | 1.2 | Ceteareth-12 |
SP BRIJ CS20 MBAL | 1.2 | Ceteareth-20 |
Cetiol V | 3.9 | Decyl Oleate |
Phase B | ||
Aqua | 63.6 | Water |
Glycerine Vegetale PH | 4.9 | Glycerine |
Kathon CG | 0.1 | Methylchloroisothiazolinone |
Phase C | ||
REACH 103 | 19.4 | Aluminum chlorohydrate |
Phase D | ||
Extract according to the invention | 3.0 |
Weigh out phase A and heat. Weigh out phase B, homogenise and heat. Mix phase B into phase A under stirring. Weigh out phase C. Add phase C to phase B+A, with stirring. Allow to cool. Weigh phase D and add to cooled phase C+B+A, under stirring.
Raw materials | % | INCI name |
Phase A | ||
Ethanol 96% | 60.4 | Alcohol |
Phase B | ||
SP Crodamol IPM MBAL | 1.5 | Isopropyl Myristate |
Phase C | ||
D-Panthenol | 0.1 | Panthenol |
Phase D | ||
Extract according to the invention | 3.0 | |
Phase E | ||
Propellent gas | 35 |
Weigh out phase A and add phase B, under stirring. Add phase C to phase B+A, under stirring. Add phase D to phase C+B+A, under stirring. In a container, add phase E to phase D+C+B+A.
Raw materials | % | INCI name |
Phase A | ||
Water | QSP | Aqua |
Sorbate de potassium | 0.10 | Potassium sorbate |
Phase B | ||
Incroquat™ Behenyl TMS-50 | 4.00 | Behentrimonium Methosulfate (and) Cetyl Alcohol (and) Butylene Glycol |
Crodacol™ CS90 | 3.00 | Cetearyl Alcohol |
Crodamol™ CP | 6.00 | Cetyl Palmitate |
Crodamol™GTIS | 4.00 | Triisostearin |
NG Shea Unsaponifiable™ | 0.50 | Butyrospermum Parkii (Shea) Butter (and) Butyrospermum Parkii (Shea) Butter Unsaponifiables |
Dl Alpha Tocopherol | 0.20 | Tocopherol |
Phase C | ||
Glycerin | 5.00 | Glycerin |
Phenoxyethanol | 0.80 | Phenoxyethanol |
Phase D | ||
Extract according to the invention | 2.00 | |
Phase E | ||
Water | 1.00 | Aqua |
Sodium Hydroxide 30% | 0.10 | Sodium Hydroxide |
Weigh out phase A and heat to 85°C in a bain-marie. Weigh out phase B and heat to 85°C in a bain-marie. Add phase B to phase A, stirring vigorously. Weigh phase C and add to phase A+B with stirring. Add phase D to phase A+B+C at around 45°C and homogenize. Weigh phase E and adjust the pH with it.
Raw materials | % | INCI name |
Phase A | ||
Water | qs | Aqua |
Xanthan gum | 0.40 | Xanthan gum |
Arlacel LC™ | 5.00 | Sorbitan stearate (and) Sorbityl laurate |
Glycerin | 1.50 | Glycerin |
Phase B | ||
Caprylic/Capric Tryglyceride | 10.00 | Caprylic/Capric Tryglyceride |
Stearyl Alcohol | 1.50 | Stearyl Alcohol |
Phase C | ||
Euxyl PE9010 | 0.1 | Phenoxyethanol (and) Ethylhexylglycerin |
Extract according to the invention | 2.0 |
Weigh the water and glycerine and add the xanthan gum. Mix until completely dispersed. Add the Arlacel™ LC and heat. Homogenise and leave to stand. Weigh phase B. Add phase B to phase A, with stirring. Weigh phase C, then add phase C to phase A+B when the temperature is below 40°C. Homogenise.
Examples of other ingredients that may be added to these formulations:
Crodarom® Nordic Cotton: active ingredient marketed by Crodarom, to help strengthen the skin's barrier function, soothe the most sensitive skin and moisturise and protect the hair.
PhytessenceTM Blue Daisy: Ingredient marketed by Crodarom, soothes sensitive skin and reduces feelings of discomfort by acting on the synthesis of inflammation mediators.
Crodarom® Bamboo Tea EC: ingredient marketed by Crodarom, stimulates cellular metabolism while maintaining the skin's moisture level, and protects the skin from external aggression.
Claims (17)
- Use of a Sichuan berry extract of Zanthoxylum bungeanum or Zanthoxylum simulans species for a non-therapeutic cosmetic of the skin and/or its appendages.
- Use according to claim 1, wherein the treatment is topical.
- Use according to claim 1 or 2, wherein the treatment is selected from:
- a body odour treatment; and/or
- an oily skin treatment, including the scalp, and the treatment of acne-prone skin; and/or
- an anti-ageing treatment; and/or
- a moisturising treatment; and/or
- a soothing treatment. - Use according to claim 3, wherein the body odour treatment is an anti-odour treatment adapted to act on the lipase activity of bacteria while preserving the bacterial flora.
- Use according to claim 3, wherein the anti-ageing treatment adapted to preserve and stimulate skin elasticity and suppleness.
- Use according to claim 3 or 5, wherein the anti-ageing is an anti-free radical and anti-glycation treatment adapted to preserve the dermal extracellular matrix.
- Use according to claim 3, wherein the oily and/or acne-prone skin treatment adapted to act on the sebum production.
- Use according to claim 3, wherein the scalp treatment is an anti-dandruff treatment adapted to act on sebum production and/or the lipase activity of bacteria.
- Use according to claim 3, wherein the moisturising treatment is adapted to act by simulating hyaluronic acid synthesis and reinforcing the skin barrier.
- Use according to claim 3, wherein the soothing treatment is adapted to act by preventing the appearance of skin micro-inflammations.
- Use according to any one of the preceding claims, wherein the treatment is adapted to improve the well-being of the consumer.
- Use according to any one of claims 1 to 11, wherein the extract is obtained by extraction under reflux, by maceration, decoction, infusion, leaching, subcritical or supercritical fluid, means of ultrasound or microwaves, percolation, digestion, cryoextraction or enzymatic digestion.
- Use according to 12, wherein the extract is obtained by digestion of Sichuan berry in aqueous, alcoholic, hydroalcoholic, glycolic or lipidic solvent, or a mixture thereof.
- Cosmetic or dermatological composition for the use according to any one of claims 1 to 11 comprising a Sichuan berry extract obtained by digestion of Sichuan berries of Zanthoxylum bungeanum or Zanthoxylum simulans species in a physiologically acceptable matrix.
- Use of a Sichuan berries extract of Zanthoxylum bungeanum or Zanthoxylum simulans species for the manufacture of a composition for the cosmetic use according to any one of claims 1 to 11.
- Use according to claim 1 to 11, wherein the treatment is a holistic treatment combining olfactory, beautifying, sensorial and emotional effects.
- Use according to claim 16, wherein:
- the olfactory effect is an anti-odour effect;
- the beautifying effect is an anti-ageing, and/or moisturizing effect, and/or reducing the skin shiny appearance;
- the sensorial effect is a soothing effect; and
- the emotional effect is a well-being effect.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR2209032 | 2022-09-09 | ||
FR2209032A FR3139467A1 (en) | 2022-09-09 | 2022-09-09 | Use of a Sichuan pepper extract for skin treatment and a composition adapted to this use. |
FRFR2302746 | 2023-03-23 | ||
FR2302746A FR3139466A1 (en) | 2022-09-09 | 2023-03-23 | Use of a Sichuan pepper extract for skin treatment and a composition adapted to this use. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024052756A1 true WO2024052756A1 (en) | 2024-03-14 |
Family
ID=88021081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/058397 WO2024052756A1 (en) | 2022-09-09 | 2023-08-24 | Use of an extract of sichuan pepper for a skin treatment and a composition suitable for this use. |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024052756A1 (en) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040151678A1 (en) * | 2000-04-10 | 2004-08-05 | Jean-Pierre Barrere | Hair care compositions |
US20070071839A1 (en) * | 2003-11-24 | 2007-03-29 | Indena S.P.A. | Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne |
US20120021082A1 (en) * | 2009-02-23 | 2012-01-26 | Christian Artaria | Cosmetic wrinkle treatment method based on a zanthoxylum bungeanum extract |
ES2408862A1 (en) * | 2011-12-16 | 2013-06-21 | Lacer, S.A. | Topical composition to relieve the skin spray. (Machine-translation by Google Translate, not legally binding) |
FR3048611A1 (en) * | 2016-03-14 | 2017-09-15 | Laboratoire Garancia | ASSOCIATION OF ZANTHOXYLUM BUNGEANUM, BENTONITE, AND ACETYL HEXAPEPTIDE 8 FOR IMPROVING THE APPEARANCE OF THE SKIN. |
CN108853249A (en) * | 2018-09-30 | 2018-11-23 | 邳州市尕星医药技术服务有限公司 | It is a kind of to treat dermopathic plastics |
CN109620881A (en) * | 2019-02-02 | 2019-04-16 | 广州富煜陇化工科技有限公司 | It is a kind of to have effects that the compound plant extract of antiphlogistic antibacterial and its application |
CN110420266A (en) * | 2019-08-11 | 2019-11-08 | 广州川研化学科技有限公司 | A kind of three green pepper anti-acne anti-mite agent |
CN111228174A (en) * | 2020-02-18 | 2020-06-05 | 广州睿森生物科技有限公司 | Skin soothing composition and skin care product |
CN111529477A (en) * | 2020-06-15 | 2020-08-14 | 云南素颜素心生物科技有限公司 | Composition for caring hair, and preparation and application thereof |
CN113318214A (en) * | 2021-05-21 | 2021-08-31 | 河北科技大学 | External composition for blackening and strengthening hair and preparation method thereof |
CN113398237A (en) * | 2021-07-06 | 2021-09-17 | 河南省纳普生物技术有限公司 | Traditional Chinese medicine composition with antibacterial, itching relieving and dandruff stopping functions and preparation method thereof |
AU2021104838A4 (en) * | 2021-08-02 | 2021-09-30 | Shanghai Yilianjiaoxin Medical Technolgy Ltd | Mechanism of skin aging reversal by active ingredient WGX-50 of Zanthoxylum bungeanum Maxim |
CN113750014A (en) * | 2021-10-14 | 2021-12-07 | 花安堂生物科技集团有限公司 | Anti-hair loss and hair-nourishing composition and preparation method and application thereof |
CN113908091A (en) * | 2021-10-14 | 2022-01-11 | 花安堂生物科技集团有限公司 | Anti-hair loss and hair-nourishing composition and preparation method and application thereof |
CN114558068A (en) * | 2022-03-16 | 2022-05-31 | 薛辉 | Preparation technology of ointment for removing dandruff and treating stubborn tinea and pruritus |
CN114907202A (en) * | 2022-06-17 | 2022-08-16 | 诺斯贝尔化妆品股份有限公司 | Preparation and application of pepper active extract, pepper polyphenol and composition thereof |
-
2023
- 2023-08-24 WO PCT/IB2023/058397 patent/WO2024052756A1/en unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040151678A1 (en) * | 2000-04-10 | 2004-08-05 | Jean-Pierre Barrere | Hair care compositions |
US20070071839A1 (en) * | 2003-11-24 | 2007-03-29 | Indena S.P.A. | Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne |
US20120021082A1 (en) * | 2009-02-23 | 2012-01-26 | Christian Artaria | Cosmetic wrinkle treatment method based on a zanthoxylum bungeanum extract |
ES2408862A1 (en) * | 2011-12-16 | 2013-06-21 | Lacer, S.A. | Topical composition to relieve the skin spray. (Machine-translation by Google Translate, not legally binding) |
FR3048611A1 (en) * | 2016-03-14 | 2017-09-15 | Laboratoire Garancia | ASSOCIATION OF ZANTHOXYLUM BUNGEANUM, BENTONITE, AND ACETYL HEXAPEPTIDE 8 FOR IMPROVING THE APPEARANCE OF THE SKIN. |
CN108853249A (en) * | 2018-09-30 | 2018-11-23 | 邳州市尕星医药技术服务有限公司 | It is a kind of to treat dermopathic plastics |
CN109620881A (en) * | 2019-02-02 | 2019-04-16 | 广州富煜陇化工科技有限公司 | It is a kind of to have effects that the compound plant extract of antiphlogistic antibacterial and its application |
CN110420266A (en) * | 2019-08-11 | 2019-11-08 | 广州川研化学科技有限公司 | A kind of three green pepper anti-acne anti-mite agent |
CN111228174A (en) * | 2020-02-18 | 2020-06-05 | 广州睿森生物科技有限公司 | Skin soothing composition and skin care product |
CN111529477A (en) * | 2020-06-15 | 2020-08-14 | 云南素颜素心生物科技有限公司 | Composition for caring hair, and preparation and application thereof |
CN113318214A (en) * | 2021-05-21 | 2021-08-31 | 河北科技大学 | External composition for blackening and strengthening hair and preparation method thereof |
CN113398237A (en) * | 2021-07-06 | 2021-09-17 | 河南省纳普生物技术有限公司 | Traditional Chinese medicine composition with antibacterial, itching relieving and dandruff stopping functions and preparation method thereof |
AU2021104838A4 (en) * | 2021-08-02 | 2021-09-30 | Shanghai Yilianjiaoxin Medical Technolgy Ltd | Mechanism of skin aging reversal by active ingredient WGX-50 of Zanthoxylum bungeanum Maxim |
CN113750014A (en) * | 2021-10-14 | 2021-12-07 | 花安堂生物科技集团有限公司 | Anti-hair loss and hair-nourishing composition and preparation method and application thereof |
CN113908091A (en) * | 2021-10-14 | 2022-01-11 | 花安堂生物科技集团有限公司 | Anti-hair loss and hair-nourishing composition and preparation method and application thereof |
CN114558068A (en) * | 2022-03-16 | 2022-05-31 | 薛辉 | Preparation technology of ointment for removing dandruff and treating stubborn tinea and pruritus |
CN114907202A (en) * | 2022-06-17 | 2022-08-16 | 诺斯贝尔化妆品股份有限公司 | Preparation and application of pepper active extract, pepper polyphenol and composition thereof |
Non-Patent Citations (2)
Title |
---|
C. ARTARIA ET AL: "Lifting properties of the alkamide fraction from the fruit husks of Zanthoxylum bungeanum", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, vol. 33, no. 4, 1 August 2011 (2011-08-01), pages 328 - 333, XP055144466, ISSN: 0142-5463, DOI: 10.1111/j.1468-2494.2010.00629.x * |
HAO DAN ET AL: "Sanshool improves UVB-induced skin photodamage by targeting JAK2/STAT3-dependent autophagy", vol. 10, no. 1, 8 January 2019 (2019-01-08), XP093035168, Retrieved from the Internet <URL:https://www.nature.com/articles/s41419-018-1261-y> DOI: 10.1038/s41419-018-1261-y * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106580797B (en) | A kind of whitening and spot eliminating cream and preparation method thereof | |
EP2370052B1 (en) | Novel sebum secretion inhibitory agent | |
JP7275103B2 (en) | Novel cosmetic use of Nephelium lapaceum extract | |
AU2011325867B2 (en) | Methods and compositions for maintaining and improving the health of skin | |
CN105496938B (en) | α-bisabolol shin moisturizer | |
WO2008139182A2 (en) | Skin care composition | |
KR20100031068A (en) | Herb cosmetic composition for skin moisturizing and soothing and method for preparing the same | |
JPWO2003072119A1 (en) | External skin composition | |
Aziz et al. | Cosmeceuticals and natural cosmetics | |
JP2015155394A (en) | photoaging inhibitor | |
EP3801778B1 (en) | Use of a bixa orellana extract | |
KR102257448B1 (en) | Cosmetic composition containing black kelp | |
KR20070011939A (en) | Cosmetic material including extract of camellia flower for skin abirritation | |
KR100981343B1 (en) | The cosmetic composition for the reduction of skin pores | |
WO2020242516A1 (en) | Skin treatment composition and preservation system | |
WO2024052756A1 (en) | Use of an extract of sichuan pepper for a skin treatment and a composition suitable for this use. | |
KR102333132B1 (en) | Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil | |
WO2022233441A1 (en) | Novel bacterial ferment of lactobacillus species | |
KR20130115566A (en) | Cosmetic composition from cephalopod extract and its fermentation | |
US20160220477A1 (en) | Cosmetic or dermatological use of an extract of tapirira guianensis | |
KR20000065305A (en) | Skin care composition containing stabilized retinol, phytosphingosine, and Castaneae crenata extracts | |
KR20090075281A (en) | Cosmetic composition with the effect of atopy skins | |
JP4773670B2 (en) | Elastin-like agent and cosmetics containing the same | |
KR102211761B1 (en) | Deosdorant cosmetic composition comprising mineral complex and methode thereof | |
FR3139466A1 (en) | Use of a Sichuan pepper extract for skin treatment and a composition adapted to this use. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23768939 Country of ref document: EP Kind code of ref document: A1 |